Quick Answer
Century Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $61.85 million for the year ending 2025.
- Century Therapeutics, Inc. showed an increase of +5.8% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Century Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $272.28 million | Q3 2021: $101.29 million | Q1 2022: $126.04 million | Q2 2022: $112.79 million | Q3 2022: $111.35 million | Q1 2023: $86.83 million | Q2 2023: $64.44 million | Q3 2023: $55.31 million | Q1 2024: $46.81 million | Q2 2024: $41.46 million | Q3 2024: $52.59 million | Q1 2025: $51.87 million | Q2 2025: $56.88 million | Q3 2025: $55.52 million.
- Over the full 6 years of available data (2020 to 2025), Century Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 127.3%.
- Historical annual values: Fiscal year 2025: $61.85 million | Fiscal year 2024: $58.44 million | Fiscal year 2023: $47.32 million | Fiscal year 2022: $84.27 million | Fiscal year 2021: $56.45 million | Fiscal year 2020: $27.21 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: